dc.identifier.uri |
http://dx.doi.org/10.15488/2698 |
|
dc.identifier.uri |
http://www.repo.uni-hannover.de/handle/123456789/2724 |
|
dc.contributor.author |
Schlatterer, Jörg
|
|
dc.contributor.author |
Breithaupt, Dietmar E.
|
|
dc.contributor.author |
Wolters, Maike
|
|
dc.contributor.author |
Hahn, Andreas
|
|
dc.date.accessioned |
2018-01-29T14:13:19Z |
|
dc.date.available |
2018-01-29T14:13:19Z |
|
dc.date.issued |
2006 |
|
dc.identifier.citation |
Schlatterer, J.; Breithaupt, D.E.; Wolters, M.; Hahn, A.: Plasma responses in human subjects after ingestions of multiple doses of natural α-cryptoxanthin: A pilot study. In: British Journal of Nutrition 96 (2006), Nr. 2, S. 371-376. DOI: https://doi.org/10.1079/BJN20061848 |
|
dc.description.abstract |
Xanthophylls have attracted a lot of interest since their health benefits were documented. Unfortunately, studying their intestinal absorption is often affected by high baseline levels present in the fasting plasma. As a-cryptoxanthin is rarely found in the traditional European diet, its concentration in human plasma is extremely low. A pilot human intervention study was designed using a-cryptoxanthin for the first time as a marker xanthophyll in a minimally formulated cellulose-based supplement. α-Cryptoxanthin was administered in gelatin soft-gel capsules in multiple doses of 156 μg/d to three male volunteers (age 27.3 (SD 4.7) years; BMI 21.6 (SD 0.3) kg/m2) for 16 d after a 2-week carotenoid depletion period. Fasting blood samples were taken before the intervention and after 3, 6, 9, 13 and 16 d. Plasma HPLC analyses allowed for determination of the concentration; liquid chromatography-MS in the single ion monitoring mode was used to confirm peak assignment. The concentrations of α-cryptoxanthin increased significantly after only 3 d of supplementation. The concentration-time plots showed a characteristic shape with a first maximum after day 6, a decline until day 9 and a gradual second rise until the end of the study. standardisation of plasma α-cryptoxanthin concentrations to triacylglycerol or total cholesterol did not influence the characteristics. The maximum concentrations reached at the end of the intervention period ranged from 0.077 to 0.160 μmol/l. These results suggest a high intestinal absorption and an enrichment of α-cryptoxanthin in the plasma even from a minimally formulated cellulose-based supplement. © The Authors 2006. |
eng |
dc.language.iso |
eng |
|
dc.publisher |
Cambridge : Cambridge University Press |
|
dc.relation.ispartofseries |
British Journal of Nutrition 96 (2006), Nr. 2 |
|
dc.rights |
Es gilt deutsches Urheberrecht. Das Dokument darf zum eigenen Gebrauch kostenfrei genutzt, aber nicht im Internet bereitgestellt oder an Außenstehende weitergegeben werden. Dieser Beitrag ist aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich. |
|
dc.subject |
α-Cryptoxanthin |
eng |
dc.subject |
Liquid chromatography-mass spectroscopy in the single ion monitoring mode |
eng |
dc.subject |
Pilot studies |
eng |
dc.subject |
Plasma xanthophyll response |
eng |
dc.subject |
alpha cryptoxanthin |
eng |
dc.subject |
carotenoid |
eng |
dc.subject |
cellulose |
eng |
dc.subject |
cholesterol |
eng |
dc.subject |
cryptoxanthin |
eng |
dc.subject |
gelatin |
eng |
dc.subject |
triacylglycerol |
eng |
dc.subject |
unclassified drug |
eng |
dc.subject |
xanthophyll |
eng |
dc.subject |
beta carotene |
eng |
dc.subject |
cryptoxanthin |
eng |
dc.subject |
drug derivative |
eng |
dc.subject |
adult |
eng |
dc.subject |
article |
eng |
dc.subject |
blood sampling |
eng |
dc.subject |
cholesterol blood level |
eng |
dc.subject |
drug absorption |
eng |
dc.subject |
drug blood level |
eng |
dc.subject |
drug capsule |
eng |
dc.subject |
drug formulation |
eng |
dc.subject |
drug isolation |
eng |
dc.subject |
high performance liquid chromatography |
eng |
dc.subject |
human |
eng |
dc.subject |
intestine absorption |
eng |
dc.subject |
liquid chromatography |
eng |
dc.subject |
male |
eng |
dc.subject |
mass spectrometry |
eng |
dc.subject |
multiple drug dose |
eng |
dc.subject |
pilot study |
eng |
dc.subject |
anthropometry |
eng |
dc.subject |
blood |
eng |
dc.subject |
drug administration |
eng |
dc.subject |
isolation and purification |
eng |
dc.subject |
methodology |
eng |
dc.subject |
microcapsule |
eng |
dc.subject |
oral drug administration |
eng |
dc.subject |
Administration, Oral |
eng |
dc.subject |
Adult |
eng |
dc.subject |
Anthropometry |
eng |
dc.subject |
beta Carotene |
eng |
dc.subject |
Capsules |
eng |
dc.subject |
Chromatography, High Pressure Liquid |
eng |
dc.subject |
Chromatography, Liquid |
eng |
dc.subject |
Drug Administration Schedule |
eng |
dc.subject |
Humans |
eng |
dc.subject |
Intestinal Absorption |
eng |
dc.subject |
Male |
eng |
dc.subject |
Mass Spectrometry |
eng |
dc.subject |
Pilot Projects |
eng |
dc.subject |
Xanthophylls |
eng |
dc.subject.ddc |
610 | Medizin, Gesundheit
|
ger |
dc.title |
Plasma responses in human subjects after ingestions of multiple doses of natural α-cryptoxanthin: A pilot study |
|
dc.type |
Article |
|
dc.type |
Text |
|
dc.relation.issn |
0007-1145 |
|
dc.relation.doi |
https://doi.org/10.1079/BJN20061848 |
|
dc.bibliographicCitation.issue |
2 |
|
dc.bibliographicCitation.volume |
96 |
|
dc.bibliographicCitation.firstPage |
371 |
|
dc.bibliographicCitation.lastPage |
376 |
|
dc.description.version |
publishedVersion |
|
tib.accessRights |
frei zug�nglich |
|